MARCH1 Deletion Attenuates HFpEF by Promoting Adipose Beiging.
Zhu Y., Fan J., Tang L., Zhou Y., Jiang K., Tan D.
Animal Study on Cardiovascular Disease, published in Compr Physiol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Compr Physiol (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41986908
- PMCID
- PMC13083538
- DOI
- 10.1002/cph4.70141
Abstract (original English)
Membrane-associated RING-CH1 (MARCH1) is a critical membrane-bound RING domain E3 ubiquitin ligase that primarily regulates immune cell development, immune responses, antigen presentation modulation, and metabolic functions. Its role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF) remains elusive. This study aimed to investigate the function of MARCH1 in HFpEF. Multi-hit (high fat/sugar diet together with deoxycorticosterone acetate and angiotensin II injection) HFpEF mouse model was established in C57BL/6 wild-type mice and MARCH1 KO mice. Non-HFpEF control mice received standard diet. Comprehensive evaluation was carried out through echocardiography, histological and biochemical studies. White adipose tissue (WAT) beiging was analyzed in isolated stromal vascular fraction cells. The relevant molecular mechanisms were determined through RNA sequencing and co-immunoprecipitation assay. Cardiometabolic dysregulation with hypertension and obesity was observed in WT HFpEF mice. Significantly reduced running distance and running time were found in HFpEF mice compared to the WT control mice (both p < 0.05). Histologic and echocardiographic examinations also visualized cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction in HFpEF mice. MARCH1 expression was significantly upregulated in the WAT of HFpEF mice. MARCH1 deficiency allevia
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev